comprehensive -WSS

comprehensive

author：leisure time 2025-08-23 08:56:39 - browse：51746

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Physician assistants need a new name. Here's what it should be

WSS

The explosion of genetic testing requires a new approach

STAT Summit: GSK CEO on pharma giant's new direction

The EU Joint Clinical Assessment needs to live up to its promise

First Opinion Podcast: Long Covid needs a new approach

Study suggests new cause of Down syndrome: cells linked to aging

Study suggests new cause of Down syndrome: cells linked to aging

focus

comprehensive

entertainment

Supreme Court strikes down use of affirmative action

Profiling embryos to choose those with higher IQs is almost a reality

Alkermes shareholders re

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Heart attack and stroke risk calculators need revising

Senate committee scrutinizes Medicare Advantage brokers

Bright Health sells Medicare Advantage business to Molina

Will Ozempic

hotspot

Studies point to risks of excluding people with obesity from drug trials

Hospital price transparency does save money, advocate argues

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Male doctors called my cancer incurable. A female doctor showed it wasn't

UnitedHealth’s board chair also owns a personal investment firm

Gene therapy denied for Afghan refugee whose father aided U.S.

Wikipedia

entertainment

Wikipedia

hotspot